DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.
Reporting from:
European Society of Cardiology Congress, Munich, August 28-1 September, 2004
Scientific Editors:
Michael Petch, Papworth Hospital, Cambridge
Man Fai Shiu, Walsgrave Hospital,
[...] Original post by admin [...]